Literature DB >> 25622977

Targeted therapies: LUX-Lung trials-not all mutations are created equal.

Lisa Hutchinson.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25622977     DOI： 10.1038/nrclinonc.2015.9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316
  1 in total
  2 in total

Review 1.  Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.

Authors:  S Morin-Ben Abdallah; V Hirsh
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 2.  Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.

Authors:  Vera Hirsh
Journal:  BioDrugs       Date:  2015-06       Impact factor: 5.807
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.